Catalyst Wire Dossier Catalyst Wire Dossier

Nurulimab

nurulimab · Biocad
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Nurulimab, covering 2025-07-08 to 2025-07-08. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma [Phase 3]

See pricing